Exelixis, Inc. (EXEL) 10-Year Financial Performance & Capital Metrics

EXEL • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

AboutExelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.Show more

Revenue $2.17B +18.5%
EBITDA $633M +222.2%
Net Income $521M +150.9%
EPS (Diluted) 1.76 +170.8%
Gross Margin 96.49% +0.5%
EBITDA Margin 29.21% +171.9%
Operating Margin 27.88% +198.6%
Net Margin 24.04% +111.7%
ROE 23.13% +164.5%
ROIC 20.57% +250.6%
Debt/Equity 0.09 +1.3%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Strong Piotroski F-Score: 8/9
✓FCF machine: 29.2% free cash flow margin
✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 17.5%
✓Share count reduced 7.9% through buybacks

✗Weaknesses

No significant weaknesses identified

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y56.18%

5Y17.51%

3Y14.76%

TTM9.93%

Profit (Net Income) CAGR

10Y-

5Y10.18%

3Y31.15%

TTM45.18%

EPS CAGR

10Y-

5Y11.53%

3Y34.71%

TTM51.28%

ROCE

10Y Avg10.26%

5Y Avg11.56%

3Y Avg12.74%

Latest23.75%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.45	53.21	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	11.82B	44.08	25.05	18.49%	29.63%	31.37%	5.36%	0.09
INBXInhibrx Biosciences, Inc.	1.07B	73.28	0.63	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.24B	6.55	-3.10		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.38B	7.94	-3.36	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	987.53M	10.14	-5.54			-33.24%		0.01
ZLABZai Lab Limited	2.07B	18.72	-7.20	49.59%	-46.83%	-27.21%		0.18
TNGXTango Therapeutics, Inc.	1.41B	10.44	-8.77	15.17%	-151.15%	-62.81%		0.18

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Jan 2025
Sales/Revenue+	37.17M	191.45M	452.48M	853.83M	967.77M	987.54M	1.43B	1.61B	1.83B	2.17B
Revenue Growth %	0.48%	4.15%	1.36%	0.89%	0.13%	0.02%	0.45%	0.12%	0.14%	0.18%
Cost of Goods Sold+	3.9M	6.55M	15.07M	26.35M	33.1M	36.27M	52.87M	57.91M	72.55M	76.22M
COGS % of Revenue	0.1%	0.03%	0.03%	0.03%	0.03%	0.04%	0.04%	0.04%	0.04%	0.04%
Gross Profit+	33.28M	184.9M	437.41M	827.48M	934.68M	951.27M	1.38B	1.55B	1.76B	2.09B
Gross Margin %	0.9%	0.97%	0.97%	0.97%	0.97%	0.96%	0.96%	0.96%	0.96%	0.96%
Gross Profit Growth %	0.44%	4.56%	1.37%	0.89%	0.13%	0.02%	0.45%	0.12%	0.13%	0.19%
Operating Expenses+	153.66M	212.11M	271.53M	388.62M	565.21M	841.21M	1.1B	1.35B	1.59B	1.49B
OpEx % of Revenue	4.13%	1.11%	0.6%	0.46%	0.58%	0.85%	0.76%	0.84%	0.87%	0.69%
Selling, General & Admin	57.3M	116.14M	159.33M	206.37M	228.24M	293.36M	401.71M	459.86M	542.71M	492.13M
SG&A % of Revenue	1.54%	0.61%	0.35%	0.24%	0.24%	0.3%	0.28%	0.29%	0.3%	0.23%
Research & Development	96.35M	95.97M	112.17M	182.26M	336.96M	547.85M	693.72M	891.81M	1.04B	910.41M
R&D % of Revenue	2.59%	0.5%	0.25%	0.21%	0.35%	0.55%	0.48%	0.55%	0.57%	0.42%
Other Operating Expenses	0	0	0	397K	680K	912K	-184K	-197K	0	85.33M
Operating Income+	-121.42M	-28.12M	165.91M	438.86M	369.47M	110.06M	286.67M	201.48M	170.88M	604.62M
Operating Margin %	-3.27%	-0.15%	0.37%	0.51%	0.38%	0.11%	0.2%	0.13%	0.09%	0.28%
Operating Income Growth %	0.46%	0.77%	6.9%	1.65%	-0.16%	-0.7%	1.6%	-0.3%	-0.15%	2.54%
EBITDA+	-120.02M	-27.12M	167.1M	443.77M	380.64M	119.2M	300.3M	222.36M	196.6M	633.42M
EBITDA Margin %	-3.23%	-0.14%	0.37%	0.52%	0.39%	0.12%	0.21%	0.14%	0.11%	0.29%
EBITDA Growth %	0.46%	0.77%	7.16%	1.66%	-0.14%	-0.69%	1.52%	-0.26%	-0.12%	2.22%
D&A (Non-Cash Add-back)	1.41M	1M	1.19M	4.92M	11.17M	9.14M	13.63M	20.88M	25.72M	28.8M
EBIT	-121.01M	-37.16M	167.11M	438.86M	398.11M	110.06M	286.67M	201.48M	170.88M	689.95M
Net Interest Income+	-39.89M	-30.48M	-3.8M	12.84M	27.96M	19.86M	7.67M	33.06M	86.54M	77.16M
Interest Income	793K	2.58M	4.88M	12.84M	27.96M	19.86M	7.67M	33.06M	86.54M	77.16M
Interest Expense	40.68M	33.06M	8.68M	0	0	0	0	0	0	0
Other Income/Expense	-40.27M	-42.1M	-7.33M	13.24M	28.64M	20.78M	7.49M	32.87M	86.64M	77.02M
Pretax Income+	-169.68M	-70.22M	158.58M	452.09M	398.11M	130.84M	294.15M	234.35M	257.52M	681.64M
Pretax Margin %	-4.56%	-0.37%	0.35%	0.53%	0.41%	0.13%	0.2%	0.15%	0.14%	0.31%
Income Tax+	55K	0	4.35M	-237.98M	77.1M	19.06M	63.09M	52.07M	49.76M	160.37M
Effective Tax Rate %	1%	1%	0.97%	1.53%	0.81%	0.85%	0.79%	0.78%	0.81%	0.76%
Net Income+	-169.74M	-70.22M	154.23M	690.07M	321.01M	111.78M	231.06M	182.28M	207.76M	521.27M
Net Margin %	-4.57%	-0.37%	0.34%	0.81%	0.33%	0.11%	0.16%	0.11%	0.11%	0.24%
Net Income Growth %	0.37%	0.59%	3.2%	3.47%	-0.53%	-0.65%	1.07%	-0.21%	0.14%	1.51%
Net Income (Continuing)	-161.74M	-70.22M	154.23M	690.07M	321.01M	111.78M	231.06M	182.28M	207.76M	521.27M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.81	-0.28	0.49	2.21	1.02	0.35	0.72	0.56	0.65	1.76
EPS Growth %	0.41%	0.65%	2.75%	3.51%	-0.54%	-0.66%	1.06%	-0.22%	0.16%	1.71%
EPS (Basic)	-0.81	-0.28	0.52	2.32	1.06	0.36	0.73	0.57	0.65	1.80
Diluted Shares Outstanding	209.23M	250.53M	312M	312.8M	315.01M	318M	322.36M	324.56M	321.46M	296.13M
Basic Shares Outstanding	209.23M	250.53M	293.59M	297.89M	302.58M	308.27M	314.88M	321.53M	318.15M	290.03M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Jan 2025
Total Current Assets+	178.66M	470.8M	484.87M	897.02M	1.01B	1.45B	1.83B	1.62B	1.32B	1.47B
Cash & Short-Term Investments	167.06M	419.8M	387.77M	693.33M	852.24M	1.21B	1.47B	1.31B	995.3M	1.11B
Cash Only	141.63M	151.69M	183.16M	314.77M	266.5M	319.22M	647.17M	501.19M	262.99M	217.37M
Short-Term Investments	25.43M	268.12M	204.61M	378.56M	585.74M	887.32M	819.9M	807.27M	732.31M	893.9M
Accounts Receivable	5.18M	40.44M	81.19M	162.77M	119.07M	160.88M	282.65M	214.78M	237.41M	265.44M
Days Sales Outstanding	50.89	77.11	65.5	69.58	44.91	59.46	71.9	48.66	47.35	44.67
Inventory	2.62M	3.34M	6.66M	9.84M	12.89M	20.97M	27.49M	33.3M	17.32M	22.39M
Days Inventory Outstanding	245.15	185.95	161.28	136.29	142.11	211.05	189.79	209.88	87.16	107.22
Other Current Assets	0	0	504K	0	0	0	0	62.21M	67.93M	68.48M
Total Non-Current Assets+	153.68M	126.74M	170.42M	525.27M	874.48M	691.94M	781.49M	1.45B	1.62B	1.48B
Property, Plant & Equipment	1.43M	2.07M	25.74M	56.76M	90.73M	67.38M	104.03M	345.44M	470.85M	359.11M
Fixed Asset Turnover	25.92x	92.45x	17.58x	15.04x	10.67x	14.66x	13.79x	4.66x	3.89x	6.04x
Goodwill	63.68M	63.68M	63.68M	63.68M	63.68M	63.68M	63.68M	63.68M	63.68M	63.68M
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	83.6M	55.6M	64.25M	157.19M	536.38M	332.31M	371.11M	756.73M	728.72M	637.29M
Other Non-Current Assets	4.96M	5.38M	16.74M	3.52M	11.31M	71.85M	131M	55.77M	0	0
Total Assets+	332.34M	597.54M	655.29M	1.42B	1.89B	2.14B	2.62B	3.07B	2.94B	2.95B
Asset Turnover	0.11x	0.32x	0.69x	0.60x	0.51x	0.46x	0.55x	0.52x	0.62x	0.74x
Asset Growth %	0.01%	0.8%	0.1%	1.17%	0.33%	0.13%	0.22%	0.17%	-0.04%	0%
Total Current Liabilities+	52.25M	270.59M	115.17M	105.47M	142.75M	204.66M	337.59M	324.36M	394.28M	403.77M
Accounts Payable	6.4M	6.57M	9.57M	10.9M	11.58M	23.63M	24.26M	32.67M	33.77M	38.19M
Days Payables Outstanding	599.84	365.72	231.97	151.01	127.72	237.81	167.46	205.9	169.89	182.9
Short-Term Debt	0	189.12M	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	1000K	1000K	1000K	1000K	1000K	1000K	1000K	0	0
Other Current Liabilities	13.21M	33.1M	52.54M	3.19M	15.13M	42.66M	45.55M	71.44M	82.12M	267.22M
Current Ratio	3.42x	1.74x	4.21x	8.50x	7.08x	7.06x	5.43x	4.99x	3.34x	3.63x
Quick Ratio	3.37x	1.73x	4.15x	8.41x	6.99x	6.96x	5.35x	4.89x	3.30x	3.58x
Cash Conversion Cycle	-303.8	-102.67	-5.2	54.86	59.3	32.7	94.23	52.64	-35.39	-31.01
Total Non-Current Liabilities+	384.39M	237.63M	255.16M	29.36M	56.95M	53.56M	68.03M	258.7M	284.17M	299.72M
Long-Term Debt	381.44M	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	14.53M	12.18M	48.01M	49.09M	51.27M	190.17M	189.94M	190.82M
Deferred Tax Liabilities	0	0	-14.53M	0	0	0	0	0	0	0
Other Non-Current Liabilities	2.96M	541K	16.64M	1.29M	2.35M	721K	8.02M	61.95M	94.22M	108.89M
Total Liabilities	436.65M	508.22M	370.33M	134.83M	199.7M	258.22M	405.62M	583.06M	678.45M	703.49M
Total Debt+	381.44M	189.12M	14.53M	14.92M	50.74M	49.09M	51.27M	190.17M	189.94M	190.82M
Net Debt	239.8M	37.44M	-168.63M	-299.86M	-215.76M	-270.13M	-595.9M	-311.02M	-73.05M	-26.55M
Debt / Equity	-	2.12x	0.05x	0.01x	0.03x	0.03x	0.02x	0.08x	0.08x	0.09x
Debt / EBITDA	-	-	0.09x	0.03x	0.13x	0.41x	0.17x	0.86x	0.97x	0.30x
Net Debt / EBITDA	-	-	-1.01x	-0.68x	-0.57x	-2.27x	-1.98x	-1.40x	-0.37x	-0.04x
Interest Coverage	-2.98x	-0.85x	19.12x	-	-	-	-	-	-	-
Total Equity+	-104.3M	89.32M	284.96M	1.29B	1.69B	1.88B	2.21B	2.49B	2.26B	2.24B
Equity Growth %	0.09%	1.86%	2.19%	3.52%	0.31%	0.11%	0.18%	0.13%	-0.09%	-0.01%
Book Value per Share	-0.50	0.36	0.91	4.12	5.35	5.91	6.86	7.67	7.04	7.58
Total Shareholders' Equity	-104.3M	89.32M	284.96M	1.29B	1.69B	1.88B	2.21B	2.49B	2.26B	2.24B
Common Stock	228K	290K	296K	300K	305K	312K	319K	324K	303K	282K
Retained Earnings	-1.94B	-1.98B	-1.83B	-880.36M	-559.35M	-447.57M	-216.51M	-34.23M	-173.35M	-98.65M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-232K	-416K	-347K	-701K	3.07M	4.48M	-758K	-14.52M	-3.75M	-1.35M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Jan 2025
Cash from Operations+	-141.59M	206.3M	165.61M	415.72M	526.96M	208.98M	400.8M	362.61M	333.32M	699.97M
Operating CF Margin %	-3.81%	1.08%	0.37%	0.49%	0.54%	0.21%	0.28%	0.23%	0.18%	0.32%
Operating CF Growth %	0.4%	2.46%	-0.2%	1.51%	0.27%	-0.6%	0.92%	-0.1%	-0.08%	1.1%
Net Income	-169.74M	-70.22M	154.23M	690.07M	321.01M	111.78M	231.06M	182.28M	207.76M	521.27M
Depreciation & Amortization	1.41M	1M	1.19M	7.77M	8.35M	9.14M	13.63M	20.88M	25.72M	28.8M
Stock-Based Compensation	21.98M	22.91M	23.94M	44.32M	56.6M	105.07M	119.82M	107.57M	106.34M	93.84M
Deferred Taxes	436K	11.41M	3.26M	-244.11M	71M	15.27M	46.53M	-60.36M	-133.21M	-59.46M
Other Non-Cash Items	30.18M	13.93M	-10.05M	-2.57M	2.91M	7.87M	28.77M	125.04M	140.68M	128.98M
Working Capital Changes	-25.84M	227.27M	-6.95M	-79.76M	67.08M	-40.14M	-39.01M	-12.8M	-13.97M	-13.45M
Change in Receivables	-646K	-37M	-40.84M	-85.47M	43.72M	-42.47M	-122.32M	66.85M	-22.62M	-27.95M
Change in Inventory	-235K	-722K	-3.32M	-3.18M	-5.73M	-21.9M	-13.21M	-11.68M	-12.98M	5.45M
Change in Payables	-1.28M	164K	3.01M	856K	39.69M	50.51M	55.09M	23.36M	53.25M	-21.89M
Cash from Investing+	50.08M	-216.05M	35.8M	-297.85M	-587.25M	-131.22M	-42.88M	-524.41M	-26.95M	-116.78M
Capital Expenditures	-447K	-1.7M	-21.14M	-33.3M	-12.83M	-30.34M	-54.23M	-27.71M	-40.47M	-28.43M
CapEx % of Revenue	0.01%	0.01%	0.05%	0.04%	0.01%	0.03%	0.04%	0.02%	0.02%	0.01%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	15.48M	-1.4M	-1M	308K	0	0	-10M	-110.75M	-122.5M	-37.75M
Cash from Financing+	152.75M	19.8M	-169.93M	9.69M	12.55M	-25.13M	-14.8M	586K	-546.05M	-628.81M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	23.41M	15.86M	9.7M	12.55M	-25.13M	-14.8M	586K	4.33M	23.23M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-142.03M	204.59M	144.47M	382.42M	514.12M	178.64M	336.58M	224.16M	170.35M	633.79M
FCF Margin %	-3.82%	1.07%	0.32%	0.45%	0.53%	0.18%	0.23%	0.14%	0.09%	0.29%
FCF Growth %	0.4%	2.44%	-0.29%	1.65%	0.34%	-0.65%	0.88%	-0.33%	-0.24%	2.72%
FCF per Share	-0.68	0.82	0.46	1.22	1.63	0.56	1.04	0.69	0.53	2.14
FCF Conversion (FCF/Net Income)	0.83x	-2.94x	1.07x	0.60x	1.64x	1.87x	1.73x	1.99x	1.60x	1.34x
Interest Paid	19.82M	21.04M	20.46M	0	0	0	0	0	0	0
Taxes Paid	192K	190K	538K	10.68M	7.87M	4.12M	12.96M	127.87M	185.66M	170.48M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-78.62%	82.41%	87.77%	21.59%	6.27%	11.3%	7.76%	8.74%	23.13%
Return on Invested Capital (ROIC)	-60.32%	-16.09%	102.38%	59.63%	22.55%	5.36%	13.34%	7.97%	5.87%	20.57%
Gross Margin	89.52%	96.58%	96.67%	96.91%	96.58%	96.33%	96.32%	96.41%	96.04%	96.49%
Net Margin	-456.63%	-36.68%	34.09%	80.82%	33.17%	11.32%	16.1%	11.31%	11.35%	24.04%
Debt / Equity	-	2.12x	0.05x	0.01x	0.03x	0.03x	0.02x	0.08x	0.08x	0.09x
Interest Coverage	-2.98x	-0.85x	19.12x	-	-	-	-	-	-	-
FCF Conversion	0.83x	-2.94x	1.07x	0.60x	1.64x	1.87x	1.73x	1.99x	1.60x	1.34x
Revenue Growth	48.03%	415.05%	136.34%	88.7%	13.35%	2.04%	45.31%	12.27%	13.6%	18.49%

Revenue by Segment

	2017	2018	2019	2020	2021	2022	2023	2024
Product, Gross	-	738.53M	957.62M	962.59M	1.45B	1.95B	2.27B	2.52B
Product, Gross Growth	-	-	29.67%	0.52%	50.94%	34.29%	16.47%	10.81%
Product	-	619.28M	759.95M	741.55M	1.08B	1.4B	1.63B	1.81B
Product Growth	-	-	22.72%	-2.42%	45.27%	30.08%	16.25%	11.08%
Collaboration	-	-	207.82M	245.99M	357.71M	209.82M	201.33M	359.31M
Collaboration Growth	-	-	-	18.36%	45.42%	-41.34%	-4.05%	78.47%
License	-	192.19M	-	167.29M	-	162.06M	178.63M	349.24M
License Growth	-	-	-	-	-	-	10.23%	95.51%
Service	-	-	-	78.69M	-	47.76M	22.69M	10.06M
Service Growth	-	-	-	-	-	-	-52.49%	-55.66%
Product, Sales Discounts And Allowances	-	-	-197.67M	-221.04M	-375.66M	-549.93M	-643.65M	-708.85M
Product, Sales Discounts And Allowances Growth	-	-	-	-11.82%	-69.95%	-46.39%	-17.04%	-10.13%
Cabometyx	324M	599.95M	733.42M	-	-	-	-	-
Cabometyx Growth	-	85.17%	22.25%	-	-	-	-	-
Collaboration, License	-	-	161.3M	-	-	-	-	-
Collaboration, License Growth	-	-	-	-	-	-	-	-
Collaboration, Research And Development Service	-	-	49.97M	-	-	-	-	-
Collaboration, Research And Development Service Growth	-	-	-	-	-	-	-	-
Cometriq	-	19.33M	26.53M	-	-	-	-	-
Cometriq Growth	-	-	37.22%	-	-	-	-	-
Collaboration, Other	-	-	-3.44M	-	-	-	-	-
Collaboration, Other Growth	-	-	-	-	-	-	-	-
Sales Discounts And Allowances	-	119.25M	-	-	-	-	-	-
Sales Discounts And Allowances Growth	-	-	-	-	-	-	-	-
Research and Development	-	39.5M	-	-	-	-	-	-
Research and Development Growth	-	-	-	-	-	-	-	-
Other Collaboration	-	2.86M	-	-	-	-	-	-
Other Collaboration Growth	-	-	-	-	-	-	-	-

Revenue by Geography

	2017	2018	2019	2020	2021	2022	2023	2024
UNITED STATES	367.91M	632.93M	770.24M	752.89M	1.09B	1.41B	1.65B	1.82B
UNITED STATES Growth	-	72.03%	21.70%	-2.25%	44.70%	29.77%	16.41%	10.77%
Europe	69.79M	182.88M	152.77M	151.63M	302.07M	168.59M	144.97M	318.63M
Europe Growth	-	162.03%	-16.46%	-0.75%	99.22%	-44.19%	-14.01%	119.79%
JAPAN	-	-	44.76M	83.02M	43.5M	28.73M	39.49M	27.08M
JAPAN Growth	-	-	-	85.47%	-47.60%	-33.96%	37.47%	-31.44%
Other Geographical Areas	-	38.02M	-	-	-	-	-	-
Other Geographical Areas Growth	-	-	-	-	-	-	-	-
World	14.78M	-	-	-	-	-	-	-
World Growth	-	-	-	-	-	-	-	-

Frequently Asked Questions

Valuation & Price

Exelixis, Inc. (EXEL) has a price-to-earnings (P/E) ratio of 25.0x. This suggests investors expect higher future growth.

Growth & Financials

Exelixis, Inc. (EXEL) reported $2.29B in revenue for fiscal year 2024. This represents a 690% increase from $289.6M in 2011.

Exelixis, Inc. (EXEL) grew revenue by 18.5% over the past year. This is strong growth.

Yes, Exelixis, Inc. (EXEL) is profitable, generating $677.9M in net income for fiscal year 2024 (24.0% net margin).

Dividend & Returns

Exelixis, Inc. (EXEL) has a return on equity (ROE) of 23.1%. This is excellent, indicating efficient use of shareholder capital.

Exelixis, Inc. (EXEL) generated $753.1M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...

Exelixis, Inc. (EXEL) 10-Year Financial Performance & Capital Metrics

EXEL • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

Revenue $2.17B +18.5%
EBITDA $633M +222.2%
Net Income $521M +150.9%
EPS (Diluted) 1.76 +170.8%
Gross Margin 96.49% +0.5%
EBITDA Margin 29.21% +171.9%
Operating Margin 27.88% +198.6%
Net Margin 24.04% +111.7%
ROE 23.13% +164.5%
ROIC 20.57% +250.6%
Debt/Equity 0.09 +1.3%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Strong Piotroski F-Score: 8/9
✓FCF machine: 29.2% free cash flow margin
✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 17.5%
✓Share count reduced 7.9% through buybacks

✗Weaknesses

No significant weaknesses identified

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y56.18%

5Y17.51%

3Y14.76%

TTM9.93%

Profit (Net Income) CAGR

10Y-

5Y10.18%

3Y31.15%

TTM45.18%

EPS CAGR

10Y-

5Y11.53%

3Y34.71%

TTM51.28%

ROCE

10Y Avg10.26%

5Y Avg11.56%

3Y Avg12.74%

Latest23.75%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.45	53.21	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	11.82B	44.08	25.05	18.49%	29.63%	31.37%	5.36%	0.09
INBXInhibrx Biosciences, Inc.	1.07B	73.28	0.63	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.24B	6.55	-3.10		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.38B	7.94	-3.36	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	987.53M	10.14	-5.54			-33.24%		0.01
ZLABZai Lab Limited	2.07B	18.72	-7.20	49.59%	-46.83%	-27.21%		0.18
TNGXTango Therapeutics, Inc.	1.41B	10.44	-8.77	15.17%	-151.15%	-62.81%		0.18

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Jan 2025
Sales/Revenue+	37.17M	191.45M	452.48M	853.83M	967.77M	987.54M	1.43B	1.61B	1.83B	2.17B
Revenue Growth %	0.48%	4.15%	1.36%	0.89%	0.13%	0.02%	0.45%	0.12%	0.14%	0.18%
Cost of Goods Sold+	3.9M	6.55M	15.07M	26.35M	33.1M	36.27M	52.87M	57.91M	72.55M	76.22M
COGS % of Revenue	0.1%	0.03%	0.03%	0.03%	0.03%	0.04%	0.04%	0.04%	0.04%	0.04%
Gross Profit+	33.28M	184.9M	437.41M	827.48M	934.68M	951.27M	1.38B	1.55B	1.76B	2.09B
Gross Margin %	0.9%	0.97%	0.97%	0.97%	0.97%	0.96%	0.96%	0.96%	0.96%	0.96%
Gross Profit Growth %	0.44%	4.56%	1.37%	0.89%	0.13%	0.02%	0.45%	0.12%	0.13%	0.19%
Operating Expenses+	153.66M	212.11M	271.53M	388.62M	565.21M	841.21M	1.1B	1.35B	1.59B	1.49B
OpEx % of Revenue	4.13%	1.11%	0.6%	0.46%	0.58%	0.85%	0.76%	0.84%	0.87%	0.69%
Selling, General & Admin	57.3M	116.14M	159.33M	206.37M	228.24M	293.36M	401.71M	459.86M	542.71M	492.13M
SG&A % of Revenue	1.54%	0.61%	0.35%	0.24%	0.24%	0.3%	0.28%	0.29%	0.3%	0.23%
Research & Development	96.35M	95.97M	112.17M	182.26M	336.96M	547.85M	693.72M	891.81M	1.04B	910.41M
R&D % of Revenue	2.59%	0.5%	0.25%	0.21%	0.35%	0.55%	0.48%	0.55%	0.57%	0.42%
Other Operating Expenses	0	0	0	397K	680K	912K	-184K	-197K	0	85.33M
Operating Income+	-121.42M	-28.12M	165.91M	438.86M	369.47M	110.06M	286.67M	201.48M	170.88M	604.62M
Operating Margin %	-3.27%	-0.15%	0.37%	0.51%	0.38%	0.11%	0.2%	0.13%	0.09%	0.28%
Operating Income Growth %	0.46%	0.77%	6.9%	1.65%	-0.16%	-0.7%	1.6%	-0.3%	-0.15%	2.54%
EBITDA+	-120.02M	-27.12M	167.1M	443.77M	380.64M	119.2M	300.3M	222.36M	196.6M	633.42M
EBITDA Margin %	-3.23%	-0.14%	0.37%	0.52%	0.39%	0.12%	0.21%	0.14%	0.11%	0.29%
EBITDA Growth %	0.46%	0.77%	7.16%	1.66%	-0.14%	-0.69%	1.52%	-0.26%	-0.12%	2.22%
D&A (Non-Cash Add-back)	1.41M	1M	1.19M	4.92M	11.17M	9.14M	13.63M	20.88M	25.72M	28.8M
EBIT	-121.01M	-37.16M	167.11M	438.86M	398.11M	110.06M	286.67M	201.48M	170.88M	689.95M
Net Interest Income+	-39.89M	-30.48M	-3.8M	12.84M	27.96M	19.86M	7.67M	33.06M	86.54M	77.16M
Interest Income	793K	2.58M	4.88M	12.84M	27.96M	19.86M	7.67M	33.06M	86.54M	77.16M
Interest Expense	40.68M	33.06M	8.68M	0	0	0	0	0	0	0
Other Income/Expense	-40.27M	-42.1M	-7.33M	13.24M	28.64M	20.78M	7.49M	32.87M	86.64M	77.02M
Pretax Income+	-169.68M	-70.22M	158.58M	452.09M	398.11M	130.84M	294.15M	234.35M	257.52M	681.64M
Pretax Margin %	-4.56%	-0.37%	0.35%	0.53%	0.41%	0.13%	0.2%	0.15%	0.14%	0.31%
Income Tax+	55K	0	4.35M	-237.98M	77.1M	19.06M	63.09M	52.07M	49.76M	160.37M
Effective Tax Rate %	1%	1%	0.97%	1.53%	0.81%	0.85%	0.79%	0.78%	0.81%	0.76%
Net Income+	-169.74M	-70.22M	154.23M	690.07M	321.01M	111.78M	231.06M	182.28M	207.76M	521.27M
Net Margin %	-4.57%	-0.37%	0.34%	0.81%	0.33%	0.11%	0.16%	0.11%	0.11%	0.24%
Net Income Growth %	0.37%	0.59%	3.2%	3.47%	-0.53%	-0.65%	1.07%	-0.21%	0.14%	1.51%
Net Income (Continuing)	-161.74M	-70.22M	154.23M	690.07M	321.01M	111.78M	231.06M	182.28M	207.76M	521.27M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.81	-0.28	0.49	2.21	1.02	0.35	0.72	0.56	0.65	1.76
EPS Growth %	0.41%	0.65%	2.75%	3.51%	-0.54%	-0.66%	1.06%	-0.22%	0.16%	1.71%
EPS (Basic)	-0.81	-0.28	0.52	2.32	1.06	0.36	0.73	0.57	0.65	1.80
Diluted Shares Outstanding	209.23M	250.53M	312M	312.8M	315.01M	318M	322.36M	324.56M	321.46M	296.13M
Basic Shares Outstanding	209.23M	250.53M	293.59M	297.89M	302.58M	308.27M	314.88M	321.53M	318.15M	290.03M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Jan 2025
Total Current Assets+	178.66M	470.8M	484.87M	897.02M	1.01B	1.45B	1.83B	1.62B	1.32B	1.47B
Cash & Short-Term Investments	167.06M	419.8M	387.77M	693.33M	852.24M	1.21B	1.47B	1.31B	995.3M	1.11B
Cash Only	141.63M	151.69M	183.16M	314.77M	266.5M	319.22M	647.17M	501.19M	262.99M	217.37M
Short-Term Investments	25.43M	268.12M	204.61M	378.56M	585.74M	887.32M	819.9M	807.27M	732.31M	893.9M
Accounts Receivable	5.18M	40.44M	81.19M	162.77M	119.07M	160.88M	282.65M	214.78M	237.41M	265.44M
Days Sales Outstanding	50.89	77.11	65.5	69.58	44.91	59.46	71.9	48.66	47.35	44.67
Inventory	2.62M	3.34M	6.66M	9.84M	12.89M	20.97M	27.49M	33.3M	17.32M	22.39M
Days Inventory Outstanding	245.15	185.95	161.28	136.29	142.11	211.05	189.79	209.88	87.16	107.22
Other Current Assets	0	0	504K	0	0	0	0	62.21M	67.93M	68.48M
Total Non-Current Assets+	153.68M	126.74M	170.42M	525.27M	874.48M	691.94M	781.49M	1.45B	1.62B	1.48B
Property, Plant & Equipment	1.43M	2.07M	25.74M	56.76M	90.73M	67.38M	104.03M	345.44M	470.85M	359.11M
Fixed Asset Turnover	25.92x	92.45x	17.58x	15.04x	10.67x	14.66x	13.79x	4.66x	3.89x	6.04x
Goodwill	63.68M	63.68M	63.68M	63.68M	63.68M	63.68M	63.68M	63.68M	63.68M	63.68M
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	83.6M	55.6M	64.25M	157.19M	536.38M	332.31M	371.11M	756.73M	728.72M	637.29M
Other Non-Current Assets	4.96M	5.38M	16.74M	3.52M	11.31M	71.85M	131M	55.77M	0	0
Total Assets+	332.34M	597.54M	655.29M	1.42B	1.89B	2.14B	2.62B	3.07B	2.94B	2.95B
Asset Turnover	0.11x	0.32x	0.69x	0.60x	0.51x	0.46x	0.55x	0.52x	0.62x	0.74x
Asset Growth %	0.01%	0.8%	0.1%	1.17%	0.33%	0.13%	0.22%	0.17%	-0.04%	0%
Total Current Liabilities+	52.25M	270.59M	115.17M	105.47M	142.75M	204.66M	337.59M	324.36M	394.28M	403.77M
Accounts Payable	6.4M	6.57M	9.57M	10.9M	11.58M	23.63M	24.26M	32.67M	33.77M	38.19M
Days Payables Outstanding	599.84	365.72	231.97	151.01	127.72	237.81	167.46	205.9	169.89	182.9
Short-Term Debt	0	189.12M	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	1000K	1000K	1000K	1000K	1000K	1000K	1000K	0	0
Other Current Liabilities	13.21M	33.1M	52.54M	3.19M	15.13M	42.66M	45.55M	71.44M	82.12M	267.22M
Current Ratio	3.42x	1.74x	4.21x	8.50x	7.08x	7.06x	5.43x	4.99x	3.34x	3.63x
Quick Ratio	3.37x	1.73x	4.15x	8.41x	6.99x	6.96x	5.35x	4.89x	3.30x	3.58x
Cash Conversion Cycle	-303.8	-102.67	-5.2	54.86	59.3	32.7	94.23	52.64	-35.39	-31.01
Total Non-Current Liabilities+	384.39M	237.63M	255.16M	29.36M	56.95M	53.56M	68.03M	258.7M	284.17M	299.72M
Long-Term Debt	381.44M	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	14.53M	12.18M	48.01M	49.09M	51.27M	190.17M	189.94M	190.82M
Deferred Tax Liabilities	0	0	-14.53M	0	0	0	0	0	0	0
Other Non-Current Liabilities	2.96M	541K	16.64M	1.29M	2.35M	721K	8.02M	61.95M	94.22M	108.89M
Total Liabilities	436.65M	508.22M	370.33M	134.83M	199.7M	258.22M	405.62M	583.06M	678.45M	703.49M
Total Debt+	381.44M	189.12M	14.53M	14.92M	50.74M	49.09M	51.27M	190.17M	189.94M	190.82M
Net Debt	239.8M	37.44M	-168.63M	-299.86M	-215.76M	-270.13M	-595.9M	-311.02M	-73.05M	-26.55M
Debt / Equity	-	2.12x	0.05x	0.01x	0.03x	0.03x	0.02x	0.08x	0.08x	0.09x
Debt / EBITDA	-	-	0.09x	0.03x	0.13x	0.41x	0.17x	0.86x	0.97x	0.30x
Net Debt / EBITDA	-	-	-1.01x	-0.68x	-0.57x	-2.27x	-1.98x	-1.40x	-0.37x	-0.04x
Interest Coverage	-2.98x	-0.85x	19.12x	-	-	-	-	-	-	-
Total Equity+	-104.3M	89.32M	284.96M	1.29B	1.69B	1.88B	2.21B	2.49B	2.26B	2.24B
Equity Growth %	0.09%	1.86%	2.19%	3.52%	0.31%	0.11%	0.18%	0.13%	-0.09%	-0.01%
Book Value per Share	-0.50	0.36	0.91	4.12	5.35	5.91	6.86	7.67	7.04	7.58
Total Shareholders' Equity	-104.3M	89.32M	284.96M	1.29B	1.69B	1.88B	2.21B	2.49B	2.26B	2.24B
Common Stock	228K	290K	296K	300K	305K	312K	319K	324K	303K	282K
Retained Earnings	-1.94B	-1.98B	-1.83B	-880.36M	-559.35M	-447.57M	-216.51M	-34.23M	-173.35M	-98.65M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-232K	-416K	-347K	-701K	3.07M	4.48M	-758K	-14.52M	-3.75M	-1.35M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Jan 2025
Cash from Operations+	-141.59M	206.3M	165.61M	415.72M	526.96M	208.98M	400.8M	362.61M	333.32M	699.97M
Operating CF Margin %	-3.81%	1.08%	0.37%	0.49%	0.54%	0.21%	0.28%	0.23%	0.18%	0.32%
Operating CF Growth %	0.4%	2.46%	-0.2%	1.51%	0.27%	-0.6%	0.92%	-0.1%	-0.08%	1.1%
Net Income	-169.74M	-70.22M	154.23M	690.07M	321.01M	111.78M	231.06M	182.28M	207.76M	521.27M
Depreciation & Amortization	1.41M	1M	1.19M	7.77M	8.35M	9.14M	13.63M	20.88M	25.72M	28.8M
Stock-Based Compensation	21.98M	22.91M	23.94M	44.32M	56.6M	105.07M	119.82M	107.57M	106.34M	93.84M
Deferred Taxes	436K	11.41M	3.26M	-244.11M	71M	15.27M	46.53M	-60.36M	-133.21M	-59.46M
Other Non-Cash Items	30.18M	13.93M	-10.05M	-2.57M	2.91M	7.87M	28.77M	125.04M	140.68M	128.98M
Working Capital Changes	-25.84M	227.27M	-6.95M	-79.76M	67.08M	-40.14M	-39.01M	-12.8M	-13.97M	-13.45M
Change in Receivables	-646K	-37M	-40.84M	-85.47M	43.72M	-42.47M	-122.32M	66.85M	-22.62M	-27.95M
Change in Inventory	-235K	-722K	-3.32M	-3.18M	-5.73M	-21.9M	-13.21M	-11.68M	-12.98M	5.45M
Change in Payables	-1.28M	164K	3.01M	856K	39.69M	50.51M	55.09M	23.36M	53.25M	-21.89M
Cash from Investing+	50.08M	-216.05M	35.8M	-297.85M	-587.25M	-131.22M	-42.88M	-524.41M	-26.95M	-116.78M
Capital Expenditures	-447K	-1.7M	-21.14M	-33.3M	-12.83M	-30.34M	-54.23M	-27.71M	-40.47M	-28.43M
CapEx % of Revenue	0.01%	0.01%	0.05%	0.04%	0.01%	0.03%	0.04%	0.02%	0.02%	0.01%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	15.48M	-1.4M	-1M	308K	0	0	-10M	-110.75M	-122.5M	-37.75M
Cash from Financing+	152.75M	19.8M	-169.93M	9.69M	12.55M	-25.13M	-14.8M	586K	-546.05M	-628.81M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	23.41M	15.86M	9.7M	12.55M	-25.13M	-14.8M	586K	4.33M	23.23M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-142.03M	204.59M	144.47M	382.42M	514.12M	178.64M	336.58M	224.16M	170.35M	633.79M
FCF Margin %	-3.82%	1.07%	0.32%	0.45%	0.53%	0.18%	0.23%	0.14%	0.09%	0.29%
FCF Growth %	0.4%	2.44%	-0.29%	1.65%	0.34%	-0.65%	0.88%	-0.33%	-0.24%	2.72%
FCF per Share	-0.68	0.82	0.46	1.22	1.63	0.56	1.04	0.69	0.53	2.14
FCF Conversion (FCF/Net Income)	0.83x	-2.94x	1.07x	0.60x	1.64x	1.87x	1.73x	1.99x	1.60x	1.34x
Interest Paid	19.82M	21.04M	20.46M	0	0	0	0	0	0	0
Taxes Paid	192K	190K	538K	10.68M	7.87M	4.12M	12.96M	127.87M	185.66M	170.48M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-78.62%	82.41%	87.77%	21.59%	6.27%	11.3%	7.76%	8.74%	23.13%
Return on Invested Capital (ROIC)	-60.32%	-16.09%	102.38%	59.63%	22.55%	5.36%	13.34%	7.97%	5.87%	20.57%
Gross Margin	89.52%	96.58%	96.67%	96.91%	96.58%	96.33%	96.32%	96.41%	96.04%	96.49%
Net Margin	-456.63%	-36.68%	34.09%	80.82%	33.17%	11.32%	16.1%	11.31%	11.35%	24.04%
Debt / Equity	-	2.12x	0.05x	0.01x	0.03x	0.03x	0.02x	0.08x	0.08x	0.09x
Interest Coverage	-2.98x	-0.85x	19.12x	-	-	-	-	-	-	-
FCF Conversion	0.83x	-2.94x	1.07x	0.60x	1.64x	1.87x	1.73x	1.99x	1.60x	1.34x
Revenue Growth	48.03%	415.05%	136.34%	88.7%	13.35%	2.04%	45.31%	12.27%	13.6%	18.49%

Revenue by Segment

	2017	2018	2019	2020	2021	2022	2023	2024
Product, Gross	-	738.53M	957.62M	962.59M	1.45B	1.95B	2.27B	2.52B
Product, Gross Growth	-	-	29.67%	0.52%	50.94%	34.29%	16.47%	10.81%
Product	-	619.28M	759.95M	741.55M	1.08B	1.4B	1.63B	1.81B
Product Growth	-	-	22.72%	-2.42%	45.27%	30.08%	16.25%	11.08%
Collaboration	-	-	207.82M	245.99M	357.71M	209.82M	201.33M	359.31M
Collaboration Growth	-	-	-	18.36%	45.42%	-41.34%	-4.05%	78.47%
License	-	192.19M	-	167.29M	-	162.06M	178.63M	349.24M
License Growth	-	-	-	-	-	-	10.23%	95.51%
Service	-	-	-	78.69M	-	47.76M	22.69M	10.06M
Service Growth	-	-	-	-	-	-	-52.49%	-55.66%
Product, Sales Discounts And Allowances	-	-	-197.67M	-221.04M	-375.66M	-549.93M	-643.65M	-708.85M
Product, Sales Discounts And Allowances Growth	-	-	-	-11.82%	-69.95%	-46.39%	-17.04%	-10.13%
Cabometyx	324M	599.95M	733.42M	-	-	-	-	-
Cabometyx Growth	-	85.17%	22.25%	-	-	-	-	-
Collaboration, License	-	-	161.3M	-	-	-	-	-
Collaboration, License Growth	-	-	-	-	-	-	-	-
Collaboration, Research And Development Service	-	-	49.97M	-	-	-	-	-
Collaboration, Research And Development Service Growth	-	-	-	-	-	-	-	-
Cometriq	-	19.33M	26.53M	-	-	-	-	-
Cometriq Growth	-	-	37.22%	-	-	-	-	-
Collaboration, Other	-	-	-3.44M	-	-	-	-	-
Collaboration, Other Growth	-	-	-	-	-	-	-	-
Sales Discounts And Allowances	-	119.25M	-	-	-	-	-	-
Sales Discounts And Allowances Growth	-	-	-	-	-	-	-	-
Research and Development	-	39.5M	-	-	-	-	-	-
Research and Development Growth	-	-	-	-	-	-	-	-
Other Collaboration	-	2.86M	-	-	-	-	-	-
Other Collaboration Growth	-	-	-	-	-	-	-	-

Revenue by Geography

	2017	2018	2019	2020	2021	2022	2023	2024
UNITED STATES	367.91M	632.93M	770.24M	752.89M	1.09B	1.41B	1.65B	1.82B
UNITED STATES Growth	-	72.03%	21.70%	-2.25%	44.70%	29.77%	16.41%	10.77%
Europe	69.79M	182.88M	152.77M	151.63M	302.07M	168.59M	144.97M	318.63M
Europe Growth	-	162.03%	-16.46%	-0.75%	99.22%	-44.19%	-14.01%	119.79%
JAPAN	-	-	44.76M	83.02M	43.5M	28.73M	39.49M	27.08M
JAPAN Growth	-	-	-	85.47%	-47.60%	-33.96%	37.47%	-31.44%
Other Geographical Areas	-	38.02M	-	-	-	-	-	-
Other Geographical Areas Growth	-	-	-	-	-	-	-	-
World	14.78M	-	-	-	-	-	-	-
World Growth	-	-	-	-	-	-	-	-

Frequently Asked Questions

Valuation & Price

Exelixis, Inc. (EXEL) has a price-to-earnings (P/E) ratio of 25.0x. This suggests investors expect higher future growth.

Growth & Financials

Exelixis, Inc. (EXEL) reported $2.29B in revenue for fiscal year 2024. This represents a 690% increase from $289.6M in 2011.

Exelixis, Inc. (EXEL) grew revenue by 18.5% over the past year. This is strong growth.

Yes, Exelixis, Inc. (EXEL) is profitable, generating $677.9M in net income for fiscal year 2024 (24.0% net margin).

Dividend & Returns

Exelixis, Inc. (EXEL) has a return on equity (ROE) of 23.1%. This is excellent, indicating efficient use of shareholder capital.

Exelixis, Inc. (EXEL) generated $753.1M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.